This study represents the first comprehensive evaluation comparing intravenous and subcutaneous anti-HER2 therapies for breast cancer across multiple dimensions, including patient time burden, healthcare provider workflow, and institutional financial impact. The gene discussed is ERBB2; the disease is breast carcinoma.